Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Gjörn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Natura: Articolo
Lingua:inglese
Pubblicazione: Philipps-Universität Marburg 2023
Soggetti:
SARS-CoV-2
proteomics
COVID-19
Medizin
acute respiratory distress syndrome
Ruxolitinib
Medical sciences Medicine
Accesso online:PDF Full Text
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Publikationen im Open Access gefördert durch die UB

Documenti analoghi